Healthcare

Popular Topics in Healthcare

Explore all subjects

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

Become a GLG Client

GLG News by Medical Tourism Experts

April 4, 2008
Growth of biologics

By a GLG Expert Contributor

Analysis of: Enbrel, Perception and Remicade Fostering a New Class of Drugs (www.pharmalive.com)

This rather poorly written summary hides the potentials and pitfalls of biologics.

April 4, 2008
TEVA CAN BE FIRST TO MARKET, and IMPROVED SUPPLY DISTRIBUTION

By a GLG Expert Contributor

Analysis of: Teva to Acquire Bentley Pharmaceuticals (pharmalive.com)

The purchase of Bentley Pharmaceuticals is significant in two ways, it will assist TEVA to file for Paragraph IV filings, thereby being first to market and improved supply chain distribution in Europe.

April 1, 2008
Wyeth's Job cuts are due to Generic erosion of their marketed products.

By a GLG Expert Contributor

Analysis of: Wyeth Cutting 1,200 US Sales Jobs (www.therapeuticsdaily.com)

The article shows Wyeth as having a pattern of attrition of it's staff, or outright letting people go with severance agreements. It appears they are doing all they can to appease the shareholders. The loss of a product to TEVA is another sore for Wyeth.

March 31, 2008
"Ask Not for Whom the Bell Tolls...It Tolls for Medicare"

By a GLG Expert Contributor

Analysis of: Outlook Remains Bleak for 2 Programs (www.nytimes.com)

The Bush Administration's most recent report on the future of the Medicare and Social Security Programs released this week is at least not worse than it was a year ago. That's the good news. However, the bad news is that it is no better. The Medicare Hospital Trust Fund is expected...

March 28, 2008
SRIMEERA

By a GLG Expert Contributor

Analysis of: Gannett Co., Inc. Releases December Statistical Report (www.tradingmarkets.com)

Long Term prospectus for Newspapers are actually bleak. Reasons are plenty. To state a few, having been in this industry, I can share that the new digital era is taking over with technology and media support. Material reading content will shrink; browing will increase (infact it has already increased...

March 28, 2008
Co-Morbidities Associated with Psoriasis

By a GLG Expert Contributor

Analysis of: Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions (www.pharmalive.com)

Infectious diseases, caused by invading microorganisms, were the leading causes of death a century ago. Chronic diseases, caused by a variety of lifestyle habits and other factors, are the leading causes of death today.

March 27, 2008
SRIMEERA

By a GLG Expert Contributor

Analysis of: Smaller Brokers Can Add Up To Better Service (www.propertyandcasualtyinsurancenews.com)

Realty brokers are presently the king-pin on metal commodity prices. Small brokers can out perform on quality but on size as large players outperform by sheer quantity. Small brokers as a community has better reach though little un-organised. As globalisation on transactions are happening, small brokers...

March 27, 2008
R&D Spending is critical to the branded and generic markets

By a GLG Expert Contributor

Analysis of: R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 (www.pharmalive.com)

R&D spending is what provides for new drugs to be created years from now.

March 27, 2008
Pfizer should know better than to intentionally act against it's own long term interest losing the trust of MD's and people.

By a GLG Expert Contributor

Analysis of: Pfizer On The Hook For Off-Label Generic Use (www.pharmalot.com)

Pfizer will loose no matter what, even if they are vindicated, as they have lost time and money in court.

March 26, 2008
Adulterated Chinese Heparin, It Happens.

By a GLG Expert Contributor

Analysis of: Heparin Find May Point to Chinese Counterfeiting (www.nytimes.com)

The FDA at the end of it's investigation finds a firm in compliance or the firm gets a form 483, the pharmaceutical version of a speeding ticket.